iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. A pre-recorded presentation by iBio will be available on demand for registered attendees and on their website from September 13. iBio specializes in sustainable, plant-based pharmaceuticals through its FastPharming Manufacturing System®, developing treatments for cancer, fibrotic, and infectious diseases, while also providing contract development services.

Positive

• Participation in a prominent investment conference could enhance visibility and attract investor interest.
• The FastPharming Manufacturing System® may provide competitive advantages in biopharmaceuticals.

Negative

• No specific new product announcements or financial metrics were provided, which may leave investors seeking more detailed insights.

BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System^®, today announced that it will participate in the H.C. Wainwright 23^rd Annual Global Investment Conference, to be held virtually September 13-15, 2021.

iBio's pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, September 13, 2021, the presentation will also be available on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System^® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering™ Development Services for advanced recombinant protein design. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

When will iBio's presentation be available during the H.C. Wainwright conference?

iBio's pre-recorded presentation will be available on demand starting September 13, 2021.

What is the focus of iBio's FastPharming Manufacturing System®?

The FastPharming Manufacturing System® focuses on sustainable, plant-based production of biopharmaceuticals, including monoclonal antibodies and vaccines.

What types of diseases is iBio developing treatments for?

iBio is developing treatments for cancers, fibrotic diseases, and infectious diseases.